MiniVax, Inc. and the University of Rochester have entered into an exclusive option agreement to develop a monoclonal antibody for the treatment of Pneumocystis pneumonia based on research conducted at the university. Pneumocystis pneumonia is an often fatal fungal respiratory infection that affects immunocompromised patients.

January 9, 2014 – Read more at BusinessWire